These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 31816431)

  • 1. SGLT2 inhibition increases serum copeptin in young adults with type 1 diabetes.
    Lytvyn Y; Bjornstad P; Katz A; Singh SK; Godoy LC; Chung LT; Vinovskis CL; Pyle L; Roussel R; Perkins BA; Cherney D
    Diabetes Metab; 2020 Jun; 46(3):203-209. PubMed ID: 31816431
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
    Cherney DZ; Perkins BA; Soleymanlou N; Maione M; Lai V; Lee A; Fagan NM; Woerle HJ; Johansen OE; Broedl UC; von Eynatten M
    Circulation; 2014 Feb; 129(5):587-97. PubMed ID: 24334175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of dapagliflozin on volume status and systemic haemodynamics in patients with chronic kidney disease without diabetes: Results from DAPASALT and DIAMOND.
    Sen T; Scholtes R; Greasley PJ; Cherney DZI; Dekkers CCJ; Vervloet M; Danser AHJ; Barbour SJ; Karlsson C; Hammarstedt A; Li Q; Laverman GD; Bjornstad P; van Raalte DH; Heerspink HJL
    Diabetes Obes Metab; 2022 Aug; 24(8):1578-1587. PubMed ID: 35478433
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of hyperglycemia and empagliflozin on markers of cardiorenal injury and inflammation in patients with type 1 diabetes.
    Kugathasan L; Sridhar VS; Lytvyn Y; Lovblom LE; Perkins BA; Advani A; Cherney DZI
    Diabetes Res Clin Pract; 2024 Jul; 213():111764. PubMed ID: 38960044
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vasopressin associated with renal vascular resistance in adults with longstanding type 1 diabetes with and without diabetic kidney disease.
    Piani F; Reinicke T; Lytvyn Y; Melena I; Lovblom LE; Lai V; Tse J; Cham L; Orszag A; Perkins BA; Cherney DZI; Bjornstad P
    J Diabetes Complications; 2021 Mar; 35(3):107807. PubMed ID: 33288413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Copeptin, a surrogate marker for arginine vasopressin, is associated with declining glomerular filtration in patients with diabetes mellitus (ZODIAC-33).
    Boertien WE; Riphagen IJ; Drion I; Alkhalaf A; Bakker SJ; Groenier KH; Struck J; de Jong PE; Bilo HJ; Kleefstra N; Gansevoort RT
    Diabetologia; 2013 Aug; 56(8):1680-8. PubMed ID: 23624546
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acute and Chronic Effects of SGLT2 Inhibitor Empagliflozin on Renal Oxygenation and Blood Pressure Control in Nondiabetic Normotensive Subjects: A Randomized, Placebo-Controlled Trial.
    Zanchi A; Burnier M; Muller ME; Ghajarzadeh-Wurzner A; Maillard M; Loncle N; Milani B; Dufour N; Bonny O; Pruijm M
    J Am Heart Assoc; 2020 Jul; 9(13):e016173. PubMed ID: 32567439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
    Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Elevated copeptin, arterial stiffness, and elevated albumin excretion in adolescents with type 1 diabetes.
    Wiromrat P; Bjornstad P; Vinovskis C; Chung LT; Roncal C; Pyle L; Lanaspa MA; Johnson RJ; Cherney DZ; Reznick-Lipina TK; Bishop F; Maahs DM; Wadwa RP
    Pediatr Diabetes; 2019 Dec; 20(8):1110-1117. PubMed ID: 31433534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated copeptin is associated with atherosclerosis and diabetic kidney disease in adults with type 1 diabetes.
    Bjornstad P; Maahs DM; Jensen T; Lanaspa MA; Johnson RJ; Rewers M; Snell-Bergeon JK
    J Diabetes Complications; 2016 Aug; 30(6):1093-6. PubMed ID: 27141815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Excretion of glucose analogue with SGLT2 affinity predicts response effectiveness to sodium glucose transporter 2 inhibitors in patients with type 2 diabetes mellitus.
    Geist BK; Brath H; Zisser L; Yu J; Fueger B; Nics L; Patronas EM; Kautzky-Willer A; Hacker M; Rasul S
    Eur J Nucl Med Mol Imaging; 2023 Aug; 50(10):3034-3041. PubMed ID: 37195445
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Copeptin adaptive response to SGLT2 inhibitors in patients with type 2 diabetes mellitus: The GliRACo study.
    Berton AM; Parasiliti-Caprino M; Prencipe N; Bioletto F; Lopez C; Bona C; Caputo M; Rumbolo F; Ponzetto F; Settanni F; Gasco V; Mengozzi G; Ghigo E; Grottoli S; Maccario M; Benso AS
    Front Neurosci; 2023; 17():1098404. PubMed ID: 37021137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predicted Cardiac Hemodynamic Consequences of the Renal Actions of SGLT2i in the DAPA-HF Study Population: A Mathematical Modeling Analysis.
    Yu H; Tang W; Greasley PJ; Penland RC; Boulton DW; Hallow KM
    J Clin Pharmacol; 2021 May; 61(5):636-648. PubMed ID: 33091173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
    Cherney DZI; Cooper ME; Tikkanen I; Pfarr E; Johansen OE; Woerle HJ; Broedl UC; Lund SS
    Kidney Int; 2018 Jan; 93(1):231-244. PubMed ID: 28860019
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
    van Bommel EJM; Muskiet MHA; van Baar MJB; Tonneijck L; Smits MM; Emanuel AL; Bozovic A; Danser AHJ; Geurts F; Hoorn EJ; Touw DJ; Larsen EL; Poulsen HE; Kramer MHH; Nieuwdorp M; Joles JA; van Raalte DH
    Kidney Int; 2020 Jan; 97(1):202-212. PubMed ID: 31791665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Urinary adenosine excretion in type 1 diabetes.
    Rajasekeran H; Lytvyn Y; Bozovic A; Lovshin JA; Diamandis E; Cattran D; Husain M; Perkins BA; Advani A; Reich HN; Kulasingam V; Cherney DZI
    Am J Physiol Renal Physiol; 2017 Aug; 313(2):F184-F191. PubMed ID: 28381459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renal Hemodynamic Function and RAAS Activation Over the Natural History of Type 1 Diabetes.
    Lytvyn Y; Bjornstad P; Lovshin JA; Boulet G; Farooqi MA; Lai V; Tse J; Cham L; Lovblom LE; Weisman A; Keenan HA; Brent MH; Paul N; Bril V; Advani A; Sochett E; Perkins BA; Cherney DZI
    Am J Kidney Dis; 2019 Jun; 73(6):786-796. PubMed ID: 30799029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
    Cherney D; Lund SS; Perkins BA; Groop PH; Cooper ME; Kaspers S; Pfarr E; Woerle HJ; von Eynatten M
    Diabetologia; 2016 Sep; 59(9):1860-70. PubMed ID: 27316632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.